Browsing by Author Colleoni, Marco

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 21 to 34 of 34 < previous 
Issue DateTitleAuthor(s)Citation
2008Lack of prognostic significance of ‘‘classic’’ lobular breast carcinoma: a matched, single institution seriesCoates, Alan; Colleoni, Marco; Galimberti, Viviana; Goldhirsch, Aron; Luini, Alberto; Maiorano, Eugenio; Maisonneuve, Patrick; Orvieto, Enrico; Rotmensz, N; Viale, Giuseppe; School of Public Health: Public HealthLack of prognostic significance of ‘‘classic’’ lobular breast carcinoma: a matched, single institution series, Breast Cancer Research and Treatment, vol.117,(1),2008,pp 211-214
2008Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 TrialCoates, Alan; Castiglione-Gertsch, Monica; Chirgwin, Jacquie H; Colleoni, Marco; Crivellari, Diana; Del Mastro, Lucia; Forbes, John F.; Gelber, Richard D. (Prof); Gladieff, Laurence; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Mouridsen, Henning; Paridaens, Robert; Price, Karen; Rabaglio, Manuela; Smith, Ian (Prof); Sun, Zhuoxin; Thurlimann, Beat; School of Public Health: Public HealthLetrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial, Journal of Clinical Oncology, vol.26, 12, 2008,pp 1972-1979
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2016Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00Coates, Alan; Abdi, Ehtesham A; Colleoni, Marco; et al, Various; Gelber, S.; Gianni, Lorenzo; Gomez, Henry; Gray, Katherine P; Lang, Istvan; Linderholm, Barbro K; Thurlimann, Beat; School of Public Health: Public HealthLow-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: International Breast Cancer Study Group Trial 22-00, Journal of Clinical Oncology, vol.34, 28, 2016,pp 3400-3408
2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsCoates, Alan; Bernhard, Jurg; Burstein, Harold J.; Colleoni, Marco; et al, Various; Luo, Weixiu; Pinotti, Graziella; Puglisi, Fabio; Ribi, Karin; Ruhstaller, Thomas; Spazzapan, Simon; Tondini, Carlo; School of Public Health: Public HealthPatient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials, The Lancet Oncology, vol.16, 7, 2015,pp 848-858
2008Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerCoates, Alan; Colleoni, Marco; et al, various; Golouh, Rastko; Maffini, Fausto; Maiorano, Eugenio; Mastropasqua, Mauro G.; Perin, Tiziana; Price, K N; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPredictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer, Journal of the National Cancer Institute, vol.100,(3),2008,pp 207-212
2010Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapyCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, A; Maiorano, Eugenio; Mastropasqua, Mauro G.; Price, Karen; Regan, Meredith M.; Viale, Giuseppe; School of Public Health: Public HealthPrognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy, Breast Cancer Research and Treatment, vol.121, 1,pp 211-218
2005Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index.Coates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, A; Li, Sigui; Price, K. N.; School of Public Health: Public HealthRelation between chemotherapy dose, oestrogen receptor expression, and body-mass index., The Lancet, vol.366,(9491),2005,pp 1108-1110
2015Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 TrialCoates, Alan; Colleoni, Marco; Debled, Marc; Ejlertsen, Bent; Filho, Otto Metzger; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Gusterson, B. A.; Mallon, Elizabeth; Price, Karen N; Regan, Meredith; Thurlimann, Beat; Viale, Giuseppe; Winer, Eric P.; School of Public Health: Public HealthRelative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial, Journal of Clinical Oncology, vol.33, 25, 2015,pp 2772-2779
2005Site of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group ExperienceCoates, Alan; Colleoni, Marco; Erzen, Darja; et, al; Gelber, Richard D. (Prof); Holmberg, Stig B.; Lindtner, Jurii; Mattsson, Jan E.; Rudenstam, Carl-Magnus; Snyder, Raymond; Zahrieh, David; School of Public Health: Public HealthSite of Primary Tumor Has a Prognostic Role in Operable Breast Cancer: The International Breast Cancer Study Group Experience, JOURNAL OF CLINICAL ONCOLOGY 2005, vol.23,(7),2005,pp 1390-1400
2006Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.Coates, Alan; Aebi, Stefan; Castiglione-Gertsch, Monica; Colleoni, Marco; Gelber, Richard D. (Prof); Gelber, Shari; Goldhirsch, Aron (Prof); International, B e; Price, Karen N.; School of Public Health: Public HealthTamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93., JOURNAL OF CLINICAL ONCOLOGY 2005, vol.24,(9),2006,pp 1332-1341
2005Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumorCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Collins, John; Crivellari, Diana; Erzen, Darja; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Holmberg, S.; Li, S.; Lindtner, Jurii; Murray, E.; Pagani, O.; Price, K. N.; Rudenstam, Carl-Magnus; Simoncini, Edda; Thurlimann, Beat; Veronesi, A.; School of Public Health: Public HealthTiming of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor, Annals of Oncology 2005, vol.16,(5),2005,pp 716-725
2016Timing of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VIICoates, Alan; Castiglione-Gertsch, Monica; Cole, Bernard; Colleoni, Marco; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Gruber, Guenther; Karlsson, Per; Price, Karen N; School of Public Health: Public HealthTiming of Radiation Therapy and Chemotherapy After Breast-Conserving Surgery for Node-Positive Breast Cancer: Long-Term Results From International Breast Cancer Study Group Trials VI and VII, International Journal of Radiation: Oncology - Biology - Physics, vol.96, 2, 2016,pp 273-279
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7